Faes Farma : Q4 2023 EBITDA in line, unenthusiastic FY 2023 outlook met
>Modest sales momentum, slightly softer margins - Total Q4 2023 revenues reached € 108m (+4% y-o-y vs 4% sales growth registered in Q3), broadly in line with our estimates. By division, sales of traditional products in Spain posted some sequential deterioration yet remained in positive territory y-o-y (4% y-o-y in Q4 2023 vs 6% in Q3), reflecting improving momentum in Bilastine (ophthalmic and ODT versions recently launched partially offsetting the generic competition...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.